Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production

2012 ◽  
Vol 98 (5) ◽  
pp. 1299-1307 ◽  
Author(s):  
Joy Lynne Britten ◽  
Minnie Malik ◽  
Gary Levy ◽  
Mirian Mendoza ◽  
William H. Catherino
Keyword(s):  
Extracellular Matrix ◽  
Gnrh Agonist ◽  
Gnrh Antagonist ◽  
Gonadotropin Releasing Hormone ◽  
Leuprolide Acetate ◽  
Releasing Hormone ◽  
Extracellular Matrix Production ◽  
Matrix Production

Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer

2021 ◽  
Author(s):  
Daniel J George ◽  
David P Dearnaley
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Gnrh Antagonist ◽  
Gonadotropin Releasing Hormone ◽  
Leuprolide Acetate ◽  
Phase Iii ◽  
Major Adverse Cardiovascular Events ◽  
Gnrh Analogues ◽  
Releasing Hormone ◽  
Testosterone Levels

Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and increased metabolic and cardiovascular risks. The GnRH antagonist relugolix is able to reduce serum testosterone levels in men with prostate cancer without inducing testosterone flare. In the HERO Phase III trial, relugolix was superior to leuprolide acetate at rapidly reducing testosterone and continuously suppressing testosterone, with faster post-treatment recovery of testosterone levels. Relugolix was associated with a 54% lower incidence of major adverse cardiovascular events than leuprolide acetate. As the first oral GnRH antagonist approved for the treatment of advanced prostate cancer, relugolix offers a new treatment option.

Sign in / Sign up

Export Citation Format

Share Document